CUSIP 35104E100 · who reports it, how much, and how much it matters to them
23 of the 720 hedge fund managers we track reported shares of 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) on Form 13F for 30 June 2026. Between them they reported USD 175m. The largest position belongs to Ra Capital Management, at USD 67m. The manager with the most riding on it is Acuta Capital Partners, where it is 4.7% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management1 fund on PPLI.com | USD 67m | 0.6% |
| 2 | Adage Capital Management1 fund on PPLI.com | USD 30m | 0.0% |
| 3 | Armistice Capital1 fund on PPLI.com | USD 27m | 0.3% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 9.1m | 0.0% |
| 5 | Renaissance Technologies13 funds on PPLI.com | USD 8.2m | 0.0% |
| 6 | Acuta Capital Partners2 funds on PPLI.com | USD 6.8m | 4.7% |
| 7 | RTW Investments2 funds on PPLI.com | USD 6.3m | 0.1% |
| 8 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 5.4m | 0.0% |
| 9 | Burkehill Global Management5 funds on PPLI.com | USD 3.7m | 0.1% |
| 10 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 2.7m | 0.1% |
| 11 | Brevan Howard Capital Management39 funds on PPLI.com | USD 2.4m | 0.0% |
| 12 | Persistent Asset Partners10 funds on PPLI.com | USD 1.9m | 0.6% |
| 13 | Greenland Capital Management1 fund on PPLI.com | USD 961,000 | 0.1% |
| 14 | Two Sigma Investments35 funds on PPLI.com | USD 924,000 | 0.0% |
| 15 | Engineers Gate Manager1 fund on PPLI.com | USD 907,000 | 0.0% |
| 16 | D. E. Shaw & Co.15 funds on PPLI.com | USD 590,000 | 0.0% |
| 17 | Squarepoint Ops7 funds on PPLI.com | USD 340,000 | 0.0% |
| 18 | Jain Global1 fund on PPLI.com | USD 313,000 | 0.0% |
| 19 | Marshall Wace LLP84 funds on PPLI.com | USD 284,000 | 0.0% |
| 20 | Rangeley Capital6 funds on PPLI.com | USD 279,000 | 0.3% |
| 21 | Graham Capital Management18 funds on PPLI.com | USD 160,000 | 0.0% |
| 22 | Prelude Capital Management9 funds on PPLI.com | USD 147,000 | 0.0% |
| 23 | The Quarry1 fund on PPLI.com | USD 359 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Acuta Capital Partners | USD 6.8m | 4.7% |
| 2 | Ra Capital Management | USD 67m | 0.6% |
| 3 | Persistent Asset Partners | USD 1.9m | 0.6% |
| 4 | Armistice Capital | USD 27m | 0.3% |
| 5 | Rangeley Capital | USD 279,000 | 0.3% |
| 6 | Burkehill Global Management | USD 3.7m | 0.1% |
| 7 | Greenland Capital Management | USD 961,000 | 0.1% |
| 8 | Arrowmark Colorado Holdings | USD 2.7m | 0.1% |
| 9 | RTW Investments | USD 6.3m | 0.1% |
| 10 | Adage Capital Management | USD 30m | 0.0% |
4D Molecular Therapeutics, Inc. trades under the symbol FDMT on the Nasdaq. Its CUSIP, the code used on Form 13F, is 35104E100.
23 of the 720 hedge fund managers PPLI.com tracks reported 4D Molecular Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 67m), Adage Capital Management (USD 30m), Armistice Capital (USD 27m), Citadel Advisors (USD 9.1m) and Renaissance Technologies (USD 8.2m).
23 managers in our coverage reported it, and between them they run 338 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Acuta Capital Partners, where the position was 4.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with 4D Molecular Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.